Heron Therapeutics Inc. priced a previously announced underwritten public offering of $150 million worth of shares.
Heron intends to use proceeds from the transaction for general corporate purposes, including funding its ongoing and future clinical trials for postoperative opioid HTX-011.
The company also granted the underwriter of the offering a 30-day option to purchase up to an additional $22.5 million of the common shares.
The offering is expected to close by Dec. 7, with Cantor Fitzgerald & Co. serving as its sole book-running manager.
